Balancing burdens and benefits: Ethical issues of off-label prescription pharmaceutical use

PM and R

Volumn 5, Issue 10, 2013, Pages 882-889

  Vox, Ford ^a,b   Capron, Alexander M ^c,d,e   Kraus, Marilyn F ^f,g   Alexander, G Caleb ^h,i   Kirschner, Kristi L ^j,k  

^a SHEPHERD CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f NATIONAL REHABILITATION HOSPITAL   (United States)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k Schwab Rehabilitation Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BACLOFEN; BOTULINUM TOXIN A; GABAPENTIN; MEMANTINE; NARCOTIC AGENT; PROPRANOLOL; THALIDOMIDE; TRAZODONE; ZOLPIDEM;

ALZHEIMER DISEASE; AUTISM; BLEPHAROSPASM; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CERVICAL DYSTONIA; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; EDITORIAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; FREEDOM OF INFORMATION ACT; GIFT GIVING; LICENCE; MEDICAL DOCUMENTATION; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICARE; OFF LABEL DRUG USE; PATIENT CARE; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; POSTCONCUSSION SYNDROME; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SPASTICITY; TRAUMATIC BRAIN INJURY;

BRAIN INJURIES; DRUG APPROVAL; ETHICS, MEDICAL; HUMANS; INFORMED CONSENT; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT;

EID: 84886039740     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2013.08.601     Document Type: Editorial

References (30)

1. Angell M. The Truth About the Drug Companies: How They Deceive Usand What to Do About It 2005, Random House, New York, NY.
2. Industry Funding of Medical Education: Report of an AAMC Task Force.June 2008 2008, Association of American Medical Colleges, Washington, DC.
3. Brody H. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry 2007, Rowman and Littlefield, Lanham, MD.
4. Elliott C. White Coat, Black Hat: Adventures on the Dark Side of Medicine 2010, Beacon Press, Boston, MA.
5. Weber T, Ornstien C, LaFLeur J. Dangers found in lack of safety oversight for Medicare drug benefit. May 12, 2013. Washington Post. Available at. Accessed August 12, 2013. http://articles.washingtonpost.com/2013-05-11/national/39187506_1_patients-appropriate-drugs-medicare-and-medicaid-services.
6. Off-label drug prescribing: What does it mean for you? Consumer Reports. Available at Accessed May 29, 2013. http://www.consumerreports.org/cro/2012/05/off-label-drug-prescribing-what-does-it-mean-for-you/index.htm.
7. Weber T, Ornstein C, LaFleur J. Dangers found in lack of safety oversight for Medicare drug benefit. Washington Post May 11, 2013. Available at. Accessed August 13, 2013. http://articles.washingtonpost.com/2013-05-11/national/39187506_1_patients-appropriate-drugs-medicare-and-medicaid-services.
8. Weber T, Ornstein C. Inside doctors' prescribing habits. Los Angeles Times. July 16, 2013. Available at Accessed August 13, 2013. http://articles.latimes.com/2013/jul/16/opinion/la-oe-weber-ornstein-prescription-drugs-and-doctors-20130716.
9. Goldberger JJ, Buxton AE. JAMA 2013;209:2559-2560. Available at Accessed August 13, 2013. http://jama.jamanetwork.com/article.aspx?articleid=1691756.
10. FDALabel-Full-Text Search of Drug Label Database Available at Accessed August 13, 2013. http://https://rm2.scinet.fda.gov/druglabel/.
11. Radley D.C., Finkelstein S.N., Stafford R.S. Off-label prescribing among office-based physicians. Arch Intern Med 2006, 166:1021-1026.
12. Weber T, Ornstien C, LaFLeur J. Dangers found in lack of safety oversight for Medicare drug benefit. Washington Post May 12, 2013. Available at Accessed August 12, 2013. http://articles.washingtonpost.com/2013-05-11/national/39187506_1_patients-appropriate-drugs-medicare-and-medicaid-services.
13. Rosoff PM, Coleman DL. The case for legal regulation of physicians' off-label prescribing, Notre Dame Law Review 2011;86:649-691.
14. National Commission for the Protection of Human Subjects ofBiomedical and Behavioral Research, The Belmont Report 1978, U.S. Department of Health, Education and Welfare, Washington, DC.
15. Innovation Versus Research: Guidelines, Concepts and Procedures for Differentiation. The Clinical Investigation Policy and Procedure Manual. no. 081.015. Boston, MA: Children's Hospital Boston; 2012. Available at Accessed June 10, 2013. http://childrenshospital.org/cfapps/research/data_admin/Site2206/Documents/cipp_081_015_innovation_vs_rsrch.pdf.
16. Dartmouth Institute for Health Policy and Clinical Practice, The Dartmouth Atlas of Health Care Available at Accessed June 10, 2013. http://www.dartmouthatlas.org/.
17. Walton S.M., Schumock G.T., Lee K.V., Alexander G.C., Meltzer D., Stafford R.S. Prioritizing future research on off-label prescribing: Results of a quantitative evaluation. Pharmacotherapy 2008, 28:1443-1452.
18. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America 2013, National Academies Press, Washington, DC. M. Smith, R. Saunders, L. Stuckhardt, J.R. McGinnis (Eds.).
19. Radley D.C., Finkelstein S.N., Stafford R.S. Off-label prescribing among office-based physicians. Arch Intern Med 2006, 166:1021-1026.
20. Chen D.T., Wynia M.K., Moloney R.M., Alexander G.C. Physician knowledge of the FDA-approved indications of commonly prescribed drugs: Results of a national survey. Pharmacoepidemiol Drug Saf 2009, 18:1094-1100.
21. Mechanic D., Aiken L.H., Greenley J.R., Slesinger D.P., Svarstad B.L., Tessler R. Physician-patient communication and patient conformity with medical advice. The Growth of Bureaucratic Medicine: An Inquiry into the Dynamics of Patient Behavior and the Organization of Medical Care 1976, 220-238. Wiley-Interscience, New York, NY.
22. Stevenson F.A., Barry C.A., Britten N., Barber N., Bradley C.P. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med 2000, 50:829-840.
23. Gillick M.R. Controlling off-label medication use. Ann Intern Med 2009, 150:344-347.
24. Schiff G.D., Galanter W.L., Duhig J., Lodolce A.E., Koronkowski M.J., Lambert B.L. Principles of conservative prescribing. Arch Intern Med 2011, 171:1433-1440.
25. Walton S.M., Schumock G.T., Lee K.V., Alexander G.C., Meltzer D., Stafford R.S. Prioritizing medications for policy and research initiatives examining off-label prescribing. Pharmacotherapy 2008, 28:1443-1452.
26. Meehan W.P. Medical therapies for concussion. Clin Sports Med 2012, 30:115.
27. Kraus M.F., Smith G.S., Butters M., et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: A study using positron emission tomography (PET). Brain Inj 2005, 19:471-479.
28. Giacino J.T., Whyte J., Bagiella E., et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. NEngl J Med 2012, 366:819-826.
29. Reddy C.C., Collins M., Lovell M., Kontos A.P. Efficacy of amantadine treatment on symptoms and neurocognitive performance among adolescents following sports-related concussion. JHead Trauma Rehab 2013, 28:260-265.
30. Tra B.S., Mulholland J.D., Kadam S.D., Johnston M.V., Comi A.M. Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. Pediatr Res 2008, 64:81-85.